Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(2024) In Seminars in Arthritis and Rheumatism 65.- Abstract
Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0–10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed... (More)
Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0–10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. Results: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84–1.02]). Conclusion: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
(Less)
- author
- organization
- publishing date
- 2024-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biologic therapy, Clinical study in epidemiology, Cohort study, Rheumatic diseases, Spondyloarthritis
- in
- Seminars in Arthritis and Rheumatism
- volume
- 65
- article number
- 152388
- publisher
- W.B. Saunders
- external identifiers
-
- pmid:38301349
- scopus:85184021202
- ISSN
- 0049-0172
- DOI
- 10.1016/j.semarthrit.2024.152388
- language
- English
- LU publication?
- yes
- id
- 97abcac4-919a-410e-bee6-718696f722a6
- date added to LUP
- 2024-02-22 15:51:38
- date last changed
- 2024-04-23 16:14:04
@article{97abcac4-919a-410e-bee6-718696f722a6,
abstract = {{<p>Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0–10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. Results: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84–1.02]). Conclusion: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.</p>}},
author = {{Christiansen, Sara Nysom and Horskjær Rasmussen, Simon and Pons, Marion and Michelsen, Brigitte and Glintborg, Bente and Gudbjornsson, Bjorn and Grondal, Gerdur and Vencovsky, Jiri and Loft, Anne Gitte and Rotar, Ziga and Pirkmajer, Katja Perdan and Nissen, Michael J. and Baranová, Jana and Macfarlane, Gary J. and Jones, Gareth T. and Iannone, Florenzo and Caporali, Roberto and Laas, Karin and Vorobjov, Sigrid and Giuseppe, Daniela Di and Olofsson, Tor and Provan, Sella Aarrestad and Fagerli, Karen Minde and Castrejon, Isabel and Otero-Varela, Lucia and van de Sande, Marleen and van der Horst-Bruinsma, Irene and Nordström, Dan and Kuusalo, Laura and Bernardes, Miguel and Hetland, Merete Lund and Østergaard, Mikkel and Midtbøll Ørnbjerg, Lykke}},
issn = {{0049-0172}},
keywords = {{Biologic therapy; Clinical study in epidemiology; Cohort study; Rheumatic diseases; Spondyloarthritis}},
language = {{eng}},
publisher = {{W.B. Saunders}},
series = {{Seminars in Arthritis and Rheumatism}},
title = {{Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice}},
url = {{http://dx.doi.org/10.1016/j.semarthrit.2024.152388}},
doi = {{10.1016/j.semarthrit.2024.152388}},
volume = {{65}},
year = {{2024}},
}